Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: A systematic review

BMJ Open

Volumn 4, Issue 8, 2014, Pages

  McFarland, Lynne V ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT;

BACTERIAL STRAIN; BIFIDO BREVE; BIFIDO LACTIS; BIFIDO LONGUM; BIFIDOBACTERIUM BIFIDUM; CANCER PATIENT; CLOSTRIDIUM BUTYRICUM; COCHRANE LIBRARY; DYSBIOSIS; EMBASE; ESCHERICHIA COLI; EVIDENCE BASED PRACTICE; GASTROINTESTINAL INFECTION; HELICOBACTER INFECTION; HUMAN; INFORMATION RETRIEVAL; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS JOHNSONII; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; LACTOBACILLUS RHAMNOSUS; LACTOBACILLUS SALIVARIUS; MEDLINE; MICROBIOLOGY; MICROFLORA; OUTCOME ASSESSMENT; POLLEN ALLERGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; SACCHAROMYCES BOULARDII; SYSTEMATIC REVIEW; DISEASES; DRUG EFFECTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

DISEASE; DYSBIOSIS; HUMANS; MICROBIOTA; PROBIOTICS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84924590652     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005047     Document Type: Review

References (112)

1. Katan MB. Why the European Food Safety Authority was right to reject health claims for probiotics. Benef Microbes 2012;3:85-9.
2. Donovan SM, Schneeman B, Gibson GR, et al. Establishing and evaluating health claims for probiotics. Amer Soc Nutr Adv Nutri 2012;3:723-5.
3. European Food Safety Authority (EFSA). Guidance on the scientific requirements for health claims related to gut and immune function. EFSA J 2011;9:1984.
4. Binnendijk KH, Rijkers GT. What is a health benefit? An evaluation of EFSA opinions on health benefits with reference to probiotics. Benef Microbes 2013;4:223-30.
5. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010;16:2202-22.
6. Buts JP, Stilmant C, Bernasconi P, et al. Characterization of alpha, alpha-trehalase released in the intestinal lumen by the probiotic Saccharomyces boulardii. Scand J Gastroenterol 2008;43:1489-96.
7. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008;3:563-78.
8. Dethlefsen L, Huse S, Sogin ML, et al. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008;6:e280.
9. McFarland LV. Normal flora: diversity and functions. Microb Ecol Health Dis 2000;12:193-207. (Pubitemid 32065048)
10. Sanders ME. Impact of probiotics on colonizing microbiota of the gut. J Clin Gasteroenterol 2011;45:S115-19.
11. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004;42:1203-6. (Pubitemid 38332848)
12. Nylund L, Satokari R, Nikkilä J, et al. Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease. BMC Microbiol 2013;13:12.
13. Prince T, McBain AJ, O'Neill CA. Lactobacillus reuteri protects epidermal keratinocytes from Staphylococcus aureus-induced cell death by competitive exclusion. Appl Environ Microbiol 2012;78:5119-26.
14. Vitali B, Cruciani F, Baldassarre ME, et al. Dietary supplementation with probiotics during late pregnancy: outcome on vaginal microbiota and cytokine secretion. BMC Microbiol 2012;12:236.
15. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991;29:297-301.
16. Ciprandi G, Vizzaccaro A, Cirillo I, et al. Bacillus clausii exerts immuno-modulatory activity in allergic subjects: a pilot study. Eur Ann Allergy Clin Immunol 2005;37:129-34. (Pubitemid 40675868)
17. Marseglia GL, Tosca M, Cirillo I, et al. Efficacy of Bacillus clausii spores in the prevention of recurrent respiratory infections in children: a pilot study. Ther Clin Risk Manag 2007;3:13-17. (Pubitemid 46671819)
18. Iniesta M, Herrera D, Montero E, et al. Probiotic effects of orally administered Lactobacillus reuteri-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. A randomized clinical trial. J Clin Periodontol 2012;39:736-44.
19. Shah MP, Gujjari SK, Chandrasekhar VS. Evaluation of the effect of probiotic (inersan) alone, combination of probiotic with doxycycline and doxycycline alone on aggressive periodontitis - a clinical and microbiological study. J Clin Diagn Res 2013;7:595-600.
20. Teughels W, Durukan A, Ozcelik O, et al. Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: a randomized placebo-controlled study. J Clin Periodontol 2013;40:1025-35.
21. Kleessen B, Bezirtzoglou E, Matto J. Culture-based knowledge on biodiversity, development and stability of human gastrointestinal microflora. Micro Ecol Health Dis 2000;12:53-63. (Pubitemid 32056924)
22. Schmeisser C, Steele H, Streit WR. Metagenomics, biotechnology with non-culturable microbes. Appl Microbiol Biotechnol 2007;75:955-62. (Pubitemid 46944554)
23. Preidis GA, Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterol 2009;136:2015-31.
24. Aagaard K, Petrosino J, Keitel W, et al. The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J 2013;27:1012-22.
25. Handelsman J. Metagenomics: application of genomics to uncultured microorganisms. Micro Mol Biol Rev 2004;68:669-85. (Pubitemid 39628532)
26. Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome. Science 2006;312:1355-9. (Pubitemid 43839542)
27. Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol 2008;24:4-10. (Pubitemid 350190890)
28. Swidsinski A, Loening-Baucke V, Kirsch S, et al. Functional biostructure of colonic microbiota (central fermenting area, germinal stock area and separating mucus layer) in healthy subjects and patients with diarrhea treated with Saccharomyces boulardii]. Gastroenterol Clin Biol 2010;34(Suppl 1):S79-92.
29. Sanders ME, Guarner F, Guerrant R, et al. An update on the use and investigation of probiotics in health and disease. Gut 2013;62:787-96.
30. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:332-6.
31. Franks AH, Harmsen HJ, Raangs GC, et al. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol 1998;64:3336-45. (Pubitemid 28411456)
32. Wada M, Nagata S, Saito M, et al. Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies. Support Care Cancer 2010;18:751-9.
33. Odamaki T, Xiao JZ, Iwabuchi N, et al. Influence of Bifidobacterium longum BB536 intake on faecal microbiota in individuals with Japanese cedar pollinosis during the pollen season. J Med Microbiol 2007;56(Pt 10):1301-8. (Pubitemid 350105596)
34. Seki H, Shiohara M, Matsumura T, et al. Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI. Pediatr Int 2003;45:86-90. (Pubitemid 36523566)
35. Mustafa RA, Santesso N, Brozek J, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. J Clin Epidemiol 2013;66:736-42.
36. McFarland LV. Meta-analysis of probiotics for prevention of antibiotic associated diarrhea and treatment of Clostridium difficile disease. Am J Gastroenterol 2006;101:812-22.
37. McFarland LV, Goh S. Preventing pediatric antibiotic-associated diarrhea and Clostridium difficile infections with probiotics: a meta-analysis. World J Meta Anal 2013;1:102-20.
38. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013;5:CD006095.
39. Shen J, Zuo Z, Mao A. Effect of probiotics on inducing remission and maintaning therapy in ulcerative colitis, Crohn 's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 2014;20:21-35.
40. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14:2650-61.
41. McFarland LV. Meta-analysis of probiotics for the prevention of traveler' s diarrhea. Travel Med Infect Dis 2007;5:97-105. (Pubitemid 46222221)
42. Huang H, Song L, Zhao W. Effects of probiotics for the treatment of bacterial vaginosis in adult women: a meta-analysis of randomized controlled trials. Arch Gynecol Obstet 2014;289:1225-34.
43. McFarland LV, Elmer GW, McFarland M. Meta-analysis of probiotics for the prevention and treatment of acute pediatric diarrhea. Internl J Probiotics Prebiotics 2006;1:63-76.
44. Dinleyici EC, Eren M, Ozen M, et al. Effectiveness and safety of Saccharomyces boulardii for acute infectious diarrhea. Expert Opin Biol Ther 2012;12:395-410.
45. Szajewska H, Ruszczyński M, Kolaček S. Meta-analysis shows limited evidence for using Lactobacillus acidophilus LB to treat acute gastroenteritis in children. Acta Paediatr 2014;103:249-55.
46. Alvaro E, Andrieux C, Rochet V, et al. Composition and metabolism of the intestinal microbiota in consumers and non-consumers of yogurt. Br J Nutr 2007;97:126-33. (Pubitemid 46662067)
47. Zubadalashvili NG, Makhviladze MA, Diasamidze MT, et al. [The comparative study of Linex and Lacto-G in treatment of adult patients with disbacteriosis]. Russian. Georgian Med News 2009;170:38-42.
48. Klein SM, Elmer GW, McFarland LV, et al. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 1993;10:1615 -19.
49. Rochet V, Rigottier-Gois L, Ledaire A, et al. Survival of Bifidobacterium animalis DN-173 010 in the faecal microbiota after administration in lyophilised form or in fermented product-a randomised study in healthy adults. J Mol Microbiol Biotechnol 2008;14:128-36. (Pubitemid 350022342)
50. Engelbrektson AL, Korzenik JR, Sanders ME, et al. Analysis of treatment effects on the microbial ecology of the human intestine. FEMS Microbiol Ecol 2006;57:239-50. (Pubitemid 44024913)
51. Zoppi G, Cinquetti M, Benini A, et al. Modulation of the intestinal ecosystem by probiotics and lactulose in children during treatment with ceftriaxone. Curr Ther Res 2001;62:418-35. (Pubitemid 32521512)
52. Orrhage K, Brismar B, Nord CE. Effects of supplements of Bifidobacterium longum and Lactobacillus acidophilus on the intestinal microbiota during administration of clindamycin. Microb Ecol Health Dis 1994;7:17-25. (Pubitemid 2040934)
53. Larsen N, Vogensen FK, Gøbel R, et al. Predominant genera of fecal microbiota in children with atopic dermatitis are not altered by intake of probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi-07. FEMS Microbiol Ecol 2011;75:482-96.
54. Lidbeck A, Edlund C, Gustafsson JA, et al. Impact of Lactobacillus acidophilus on the normal intestinal microflora after administration of two antimicrobial agents. Infection 1988;16:329-36. (Pubitemid 19004303)
55. Black F, Einarsson K, Lidbeck A, et al. Effect of lactic acid producing bacteria on the human intestinal microflora during ampicillin treatment. Scand J Infect Dis 1991;23:247-54.
56. Jernberg C, Sullivan A, Edlund C, et al. Monitoring of antibiotic-induced alterations in the human intestinal microflora and detection of probiotic strains by use of terminal restriction fragment length polymorphism. Appl Environ Microbiol 2005;71:501-6. (Pubitemid 40116306)
57. Madden JA, Plummer SF, Tang J, et al. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study. Int Immunopharmacol 2005;5:1091-7.
58. Plummer SF, Garaiova I, Sarvotham T, et al. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int J Antimicrob Agents 2005;26:69-74. (Pubitemid 40854119)
59. van der Aa LB, Heymans HS, van Aalderen WM, et al. Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. Clin Exp Allergy 2010;40:795-804.
60. Lata J, Novotný I, Príbramská V, et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007;19:1111-13. (Pubitemid 350125383)
61. Petricevic L, Witt A. The role of Lactobacillus casei rhamnosus Lcr35 in restoring the normal vaginal flora after antibiotic treatment of bacterial vaginosis. BJOG 2008;115:1369-74.
62. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-8. (Pubitemid 30263518)
63. Klarin B, Johansson ML, Molin G, et al. Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomised open trial. Crit Care 2005;9: R285-93.
64. Klarin B, Molin G, Jeppsson B, et al. Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care 2008;12:R136.
65. Girard-Pipau F, Pompei A, Schneider S, et al. Intestinal microflora, short chain and cellular fatty acids, influence of a probiotic S. boulardii. Microb Ecology Health Dis 2002;14:220-7. (Pubitemid 36222182)
66. Swidsinski A, Loening-Baucke V, Verstraelen H, et al. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 2008;135:568-79.
67. Reid G, Beuerman D, Heinemann C, et al. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunol Med Microbiol 2001;32:37-41. (Pubitemid 34025073)
68. Reid G, Charbonneau D, Erb J, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol Med Microbiol 2003;35:131-4. (Pubitemid 36298934)
69. Kirpich IA, Solovieva NV, Leikhter SN, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 2008;42:675-82.
70. Hummelen R, Changalucha J, Butamanya NL, et al. Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HIV. Int J Gynaecol Obstet 2010;111:245-8.
71. Uchida K, Takahashi T, Inoue M, et al. Immunonutritional effects during synbiotics therapy in pediatric patients with short bowel syndrome. Pediatr Surg Int 2007;23:243-8.
72. Mastromarino P, Macchia S, Meggiorini L, et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Microbiol Infect 2009;15:67-74.
73. Roessler A, Forssten SD, Glei M, et al. The effect of probiotics on faecal microbiota and genotoxic activity of faecal water in patients with atopic dermatitis: a randomized, placebo-controlled study. Clin Nutr 2012;31:22-9.
74. Kajander K, Hatakka K, Poussa T, et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6 month intervention. Aliment Pharmacol Ther 2005;22:387-94. (Pubitemid 41248105)
75. Lyra A, Krogius-Kurikka L, Nikkilä J, et al. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol 2010;10:110.
76. Wong VW, Tse CH, Lam TT, et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis - a longitudinal study. PLoS ONE 2013;8:e62885.
77. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-8.
78. Brigidi P, Vitali B, Swennen E, et al. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001;152:735-41. (Pubitemid 32905506)
79. Kuhbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006;55:833-41. (Pubitemid 43764555)
80. Ng SC, Lam ERC, Lam TTY, et al. Effect of probiotic bacteria on the intestinal microbiota in irritable bowel syndrome. J Gastroenterol Hepatol 2013;28:1624-31.
81. Oswari H, Prayitno L, Dwipoerwantoro PG, et al. Comparison of stool microbiota compositions, stool alpha1-antitrypsin and calprotectin concentrations, and diarrhoeal morbidity of Indonesian infants fed breast milk or probiotic/prebiotic-supplemented formula. J Paediatr Child Health 2013;49:1032-9.
82. Langhendries JP, Detry J, Van Hees J, et al. Effect of a fermented infant formula containing viable Bifidobacteria on the fecal flora composition and pH of healthy full-term infants. J Ped Gastroenterol Nutr 1995;21:177-81.
83. Benno Y, Mitsuoka T. Impact of Bifidobacterium longum on human fecal microflora. Microbiol Immunol 1992;36:683-94.
84. Fujiwara S, Seto Y, Kimura A, et al. Intestinal transit of an orally administered streptomycin-rifampicin-resistant variant of Bifidobacterium longum SBT2928: its long-term survival and effect on the intestinal microflora and metabolism. J Appl Microbiol 2001;90:43-52. (Pubitemid 32150292)
85. Harmsen HJ, Raangs GC, Franks AH, et al. The effect of the prebiotic inulin and the probiotic Bifidobacterium longum on the fecal microflora of healthy volunteers measured by FISH and DGGE. Micro Ecol Health Dis 2002;14:211-19. (Pubitemid 36222181)
86. Guerin-Danan C, Chabanet C, Pedone C, et al. Milk fermented with yogurt cultures and Lactobacillus casei compared with yogurt and gelled milk: influence on intestinal microflora in healthy infants. Am J Clin Nutri 1998;67:111 -17.
87. Rochet V, Rigottier-Gois L, Sutren M, et al. Effects of orally administered Lactobacillus casei DN-114 001 on the composition or activities of the dominant faecal microbiota in healthy humans. Br J Nutr 2006;95:421-9.
88. Rochet V, Rigottier-Gois L, Levenez F, et al. Modulation of Lactobacillus casei in ileal and fecal samples from healthy volunteers after consumption of a fermented milk containing Lactobacillus casei DN-114 001. Can J Microbiol 2008;54:660-7.
89. Brunser O, Gotteland M, Cruchet S, et al. Effect of a milk formula with prebiotics on the intestinal microbiota of infants after an antibiotic treatment. Pediatr Res 2006;59:451-6. (Pubitemid 43740087)
90. Goossens D, Jonkers D, Russel M, et al. The effect of Lactobacillus plantarum 299v on the bacterial composition and metabolic activity in faeces of healthy volunteers: a placebo-controlled study on the onset and duration of effects. Aliment Pharmacol Ther 2003;18:495-505.
91. Goossens D, Jonkers D, Russel M, et al. Survival of the probiotic, L. plantarum 299v and its effects on the faecal bacterial flora, with and without gastric acid inhibition. Dig Liver Dis 2005;37:44-50. (Pubitemid 41070564)
92. Goossens DA, Jonkers DM, Russel MG, et al. The effect of a probiotic drink with Lactobacillus plantarum 299v on the bacterial composition in faeces and mucosal biopsies of rectum and ascending colon. Aliment Pharmacol Ther 2006;23:255-63. (Pubitemid 43382035)
93. Berggren A, Soderberg L, Onning G, et al. Intestinal function, microflora and nutrient intake of children after administration of a fermented oat product containing Lactobacillus plantarum DSM 9843(299v). Microb Ecol Health Dis 2003;15:160-8. (Pubitemid 38324513)
94. Karlsson C, Ahrné S, Molin G, et al. Probiotic therapy to men with incipient arteriosclerosis initiates increased bacterial diversity in colon: a randomized controlled trial. Atherosclerosis 2010;208:228-33.
95. Gueimonde M, Sakata S, Kalliomäki M, et al. Effect of maternal consumption of lactobacillus GG on transfer and establishment of fecal bifidobacterial microbiota in neonates. J Pediatr Gastroenterol Nutr 2006;42:166-70.
96. Sierra S, Lara-Villoslada F, Sempere L, et al. Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults. Anaerobe 2010;16:195-200.
97. Vanhoutte T, De Preter V, De Brandt E, et al. Molecular monitoring of the fecal microbiota of healthy human subjects during administration of lactulose and Saccharomyces boulardii. Appl Environ Microbiol 2006;72:5990-7. (Pubitemid 44414627)
98. Zhong Y, Huang CY, He T, et al. [Effect of probiotics and yogurt on colonic microflora in subjects with lactose intolerance]. Wei Sheng Yan Jiu 2006;35:587-91.
99. He T, Priebe MG, Zhong Y, et al. Effects of yogurt and bifidobacteria supplementation on the colonic microbiota in lactose-intolerant subjects. J Appl Microbiol 2008;104:595-604.
100. Yang YJ, Sheu BS. Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter 2012;17:297-304.
101. Mah KW, Chin VI, Wong WS, et al. Effect of a milk formula containing probiotics on the fecal microbiota of Asian infants at risk of atopic diseases. Pediatr Res 2007;62:674-9. (Pubitemid 350158804)
102. Rafter J, Bennett M, Caderni G, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr 2007;85:488-96. (Pubitemid 46220953)
103. Kubota A, He F, Kawase M, et al. Lactobacillus strains stabilize intestinal microbiota in Japanese cedar pollinosis patients. Microbiol Immunol 2009;53:198-205.
104. Morelli L, Zonenschain D, Callegari ML, et al. Assessment of a new synbiotic preparation in healthy volunteers: survival, persistence of probiotic strains and its effect on the indigenous flora. Nutr J 2003;2:11.
105. Sullivan A, Nord CE, Evengard B. Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. Nutr J 2009;8:1-6.
106. McNulty NP, Yatsunenko T, Hsiao A, et al. The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Sci Transl Med 2011;3:106ra106.
107. Guarner F, Khan AG, Garisch J, et al.; World Gastroenterology Organization. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012;46:468-81.
108. United States Department of Health and Human Services Food and Drug Administration, Center for Food Safety and Applied Nutrition. Dietary Supplements Guidance Documents and Regulatory Information. 2008. http://www.fda/gov/food/guidanceregulation/ guidancedocumentsregulatoryinformation/dietarysupplements/default.htm (accessed 29 May 2014).
109. Barc MC, Charrin-Sarnel C, Rochet V, et al. Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: influence of Saccharomyces boulardii. Anaerobe 2008;14:229-33.
110. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 2006;7:688-93. (Pubitemid 43986264)
111. Masood MI, Qadir MI, Shirazi JH, et al. Beneficial effects of lactic acid bacteria on human beings. Crit Rev Microbiol 2011;37:91-8.
112. Rijkers GT, de Vos WM, Brummer RJ, et al. Health benefits and health claims of probiotics: bridging science and marketing. Br J Nutr 2011;106:1291-6.